雜志介紹

Pharmacogenomics & Personalized Medicine雜志介紹

《Pharmacogenomics & Personalized Medicine》是一本以English為主的開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱(chēng)藥物基因組學(xué)和個(gè)性化醫(yī)學(xué)，本刊主要出版、報(bào)道醫(yī)學(xué)-PHARMACOLOGY & PHARMACY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專(zhuān)業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專(zhuān)業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為1.8，最新CiteScore 指數(shù)為3.3。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation

  Author: Zhong, Lan; Yin, Rutie; Song, Liang

• Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma

  Author: Zheng, Chunlan; Peng, Yanan; Wang, Haizhou; Wang, Youwei; Liu, Lan; Zhao, Qiu

• NOTCH2, ATIC, MRI1, SLC6A13, ATP13A2 Genetic Variations are Associated with Ventricular Septal Defect in the Chinese Tibetan Population Through Whole-Exome Sequencing

  Author: Zhang, Xiaohui; Zhen, Da; Li, Xuemei; Yi, Faling; Zhang, Zhanhao; Yang, Wei; Li, Xuguang; Sheng, Yemeng; Liu, Xiaoli; Jin, Tianbo; He, Yongjun

• The Allelic Expression of RNA Editing Gene ADARB1 in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

  Author: Zeng, Jiajia; Han, Linyu; Wang, Teng; Huang, Linying; Zheng, Yanxiu; Zhang, Nasha; Li, Ziqiang; Yang, Ming

英文介紹

Pharmacogenomics & Personalized Medicine雜志英文介紹

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.

In particular, emphasis will be given to:

Genomic and proteomic profiling

Genetics and drug metabolism

Targeted drug identification and discovery

Optimizing drug selection & dosage based on patient's genetic profile

Drug related morbidity & mortality intervention

Advanced disease screening and targeted therapeutic intervention

Genetic based vaccine development

Patient satisfaction and preference

Health economic evaluations

Practical and organizational issues in the development and implementation of personalized medicine programs.